ALK and cholestasis: The decreases in Alk-p and γ-GT levels in PBC patients highlight the efficacy of UDCA in improving cholestasis features, and the efficacy of UDCA has been documented to be superior to that of placebo in a multicenter, double-blind, placebo-controlled trial (23).